Programmed cell death protein 1 (PD-1) and its ligand PD-L1 have emerged as critical targets in immunotherapy for CRC, particularly in the context of microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) tumors. The gene discussed is PDCD1; the disease is colorectal carcinoma.